Biotech Distilled

Substack ↗ Subscribe

Subscribe Substack ↗ About

Research Areas Modalities Phases Targets Catalysts Track record Movers The Lead Compound

Home › Targets › Nav1.1

Nav1.1 (1 companies · 1 programs)

Companies with an active program directed at Nav1.1.

Xenon Pharmaceuticals Inc. XENE

Nav1.1 program — Dravet Syndrome Preclinical

Track record About Feedback Report a bug Substack ↗

This website is an encyclopedia of clinical-stage biotech companies, refreshed weekly. For informational and educational use only — not investment advice. Always verify against primary sources before making decisions.